Antihypertensive Treatment in Masked Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 320 participants.

Also called NCT02893358

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 320 participants (enrolled count) (from the registry)
Sponsor
Yan Li (from the registry)
Registry
  • NCT NCT02893358
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02893358. Randomized; double masking; primary purpose prevention. Start 2017-02-14 (actual); primary completion 2021-10-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Antihypertensive Treatment in Masked Hypertension
Acronym
ANTI-MASK
Condition
Masked Hypertension
Intervention (Drug)
Allisartan Isoproxil
Intervention (Drug)
Placebo
Lead sponsor
Yan Li (class: other)

Record details

Record id
cardio:ct-nct02893358
Content hash
7d9a6b221448e36239a713551167fd32ad7635ae2d7fe2a8782314bb1a5d0f7d